Recovery of visual and endocrine function following transsphenoidal surgery of large nonfunctioning pituitary adenomas.
A series of 35 patients with non-functioning pituitary adenomas undergoing transsphenoidal surgery is presented. In most cases, the presenting symptoms were related to the mass effect of the tumor. There was no operative mortality. Before surgery, visual field defects were documented in 21 patients (60%). After surgery, excluding 3 patients with preoperative blindness, 28% regained normal vision and 67% showed variable improvement. Preoperatively, 24 patients (69%) had abnormal pituitary function, 24 (69%) had hypogonadism, 7 (20%) adrenal insufficiency, 8 (23%) hypothyroidism and 2 (6%) panhypopituitarism. After pituitary surgery, all but one patient with normal preoperative function retained it. Of the patients with hypopituitarism, 11 (46%) had variable improvement and 13 (54%) had persistent deficits. After surgery, 4 patients (57%) with adrenal insufficiency recovered normal adrenal function, 7 patients (29%) with hypogonadism recovered gonadal function and 1 patient (13%) with hypothyroidism recovered thyroid function. Prior to surgery, the presence of a normal or slightly elevated PRL and a rise in TSH after TRH and in LH after GnRH stimulation were of value in predicting possible recovery of pituitary function after surgery. These observations suggest the presence of viable pituitary tissue in these cases and point out that, in some instances, the mechanism of hypopituitarism may be compression of the portal circulation, rather than destruction of the normal pituitary gland.
Marazuela
M
M
Department of Endocrinology, Clínica Puerto de Hierro San Martín de Porres, Madrid, Spain.
Astigarraga
B
B
Vicente
A
A
Estrada
J
J
Cuerda
C
C
García-Uría
J
J
Lucas
T
T
D000236:Adenoma / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D000293:Adolescent; D000328:Adult; D000368:Aged; D004702:Endocrine Glands / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007006:Hypogonadism / Q000209:etiology / Q000503:physiopathology; D007018:Hypopituitarism / Q000209:etiology / Q000503:physiopathology; D007037:Hypothyroidism / Q000209:etiology / Q000503:physiopathology; D007150:Immunohistochemistry; D007986:Luteinizing Hormone / Q000032:analysis / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010902:Pituitary Gland / Q000378:metabolism / Q000502:physiology; D010911:Pituitary Neoplasms / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D011388:Prolactin / Q000032:analysis / Q000378:metabolism; D013972:Thyrotropin / Q000032:analysis / Q000378:metabolism; D014785:Vision, Ocular / Q000502:physiology*
D011388:Prolactin; D007986:Luteinizing Hormone; D013972:Thyrotropin